奥利司他对男性腹型肥胖症患者血清Irisin影响的研究

The efect of orlistat on serum irisin level in male adults with abdominal obesity

目的观察奥利司他对男性腹型肥胖症患者血清Irisin水平的影响。方法选取2014年9月至12月在于我院门诊招募的男性肥胖患者60例（腹型肥胖定义：男性腰围≥90cm）,年龄18~65岁,随机分为两组,在轻度低热量饮食的同时给予试验组奥利司他（30例）,为期12周,观察比较体重指数、腰臀比、血脂等肥胖相关指标,并检测治疗前后血清Irisin浓度。结果经过12周的治疗,奥利可他组患者的体重指数、腰臀比降低（P〈0.05）,与对照组相比,奥利司他更能显著降低肥胖患者的血甘油三酯和胆固醇水平及低密度脂蛋白胆周醇水平（P〈0.05）;显著升高肥胖患者血清Irisin水平,试验中未发生与药物相关的严重不良事件。结论奥利司他结合轻度低热量饮食控制治疗可显著改善男性患者的肥胖状态,并升高血清Irisin水平,且安全性和耐受性好。

Objectives To study the efect of orlistat on serum irisin level of Chinesemale patientswith abdominal obesity. Methods A randomizedcontrolled clinical trial was conducted. A total of 60 subjects（ Age： 18 ~ 65 Year） with abdominal obesity（ waist circumference： male≥90 cm） were recruited from clinical（ 2014. 9 ~ 2014. 12）. All theparticipants received low energy food.30 eligible patients with obesity were randomized to orlismt for 12 weeks. Some factor about obese and serum irisinlevels was measured before and after treatment. The data were analyzed using SPSS 19. Results After 12 weeks treatment with orlistat,the serum irisin level was significantly increased compared with pretreatment. The serum TG. TC LDL-C decreases significantly after 12 weeks antiobesity treatment withorlistat. Conclusions Antiobesity treatment with orlistat and low-anergy-deary may increase the serum irisin level in male adults with abdominal obesity,and itssafety and tolerability was realiable.